Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

CorrelAtes of Protective immuniTy-driven Investigation of malaria VAccine combinaTion stratEgies

Project description

Mapping immunity to fight malaria

Hundreds of thousands of people die each year from malaria, with Plasmodium falciparum among the deadliest of human parasites. Current malaria vaccines offer only limited protection. The EU-funded CAPTIVATE project aims to target multiple stages of the parasite’s lifecycle (sporozoite, liver, and blood) through a combination of vaccination strategies. These combinations will be tested in preclinical and small-scale human trials. Using cutting-edge in-silico platforms and AI predictions, the project will also map the immune responses each combination triggers. Understanding the mechanisms of protective immunity, the project aims to develop next-generation malaria vaccines.

Objective

Malaria remains a serious health concern worldwide, with P. falciparum considered one of the deadliest human parasites. Yet, the currently approved vaccine against malaria (RTS,S/AS01) offers limited protection due to challenges in vaccine development. Using current advances made in understanding immunity to address some of the existing challenges, this proposal aims to develop a more efficacious vaccine against P. falciparum by targeting multiple developmental stages (sporozoite, liver and blood-stage). In this project, combinations of 1) highly promising whole parasite vaccination approach targeting the liver (late-arresting GAP), 2) RTS,S (provided by GSK) and 3) mRNA versions of clinically evaluated and partially protective blood stage vaccine candidates (Rh5, AMA1-DiCo [sporozoite and blood stage]) will be evaluated in preclinical and small-scale human trials to discern the optimal combination for further clinical investigations. To inform a rational design of future vaccine candidates, CAPTIVATE will analyse the vaccine-induced immune response to acquire a full understanding of malaria protective immunity and develop an advanced immunology in-silico platform. While immunity to blood stage malaria is relatively well understood, the mechanisms of adaptive protective immunity for pre-erythrocytic malaria vaccine candidates are less well-established. CAPTIVATE addresses this critical knowledge gap by combining state-of-the-art preclinical and clinical (CHMI) in vivo malaria vaccine efficacy models with an innovative in-silico platform comprising TCR/VDJ sequencing and artificial intelligence predictions, to identify such mechanisms. CAPTIVATE assembles a unique combination of European experts in their respective fields (malaria modelling in primates, clinical vaccine testing, in-silico modelling of immune responses, innovative omics approaches) in an integrated interdisciplinary approach aimed at bringing the next generation malaria vaccines to the clinic.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2022-DISEASE-06-two-stage

See all projects funded under this call

Coordinator

EUROPEAN VACCINE INITIATIVE EV
Net EU contribution
€ 944 375,00
Address
IM NEUENHEIMER FELD 515
69120 Heidelberg
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost
€ 944 375,00

Participants (7)

Partners (1)